ENTEROME ENTEROME
  • COMPANY
    • FOCUS
    • COLLABORATIONS
    • LEADERSHIP
  • TECHNOLOGY
    • PROGRAMS & PRODUCTS
  • PIPELINE
  • INVESTORS
  • NEWSROOM
    • PRESS RELEASES
    • CONFERENCES & EVENTS
  • CAREERS
  • CONTACT
ENTEROME ENTEROME
  • COMPANY
    • FOCUS
    • COLLABORATIONS
    • LEADERSHIP
  • TECHNOLOGY
    • PROGRAMS & PRODUCTS
  • PIPELINE
  • INVESTORS
  • NEWSROOM
    • PRESS RELEASES
    • CONFERENCES & EVENTS
  • CAREERS
  • CONTACT
Aug 03 2020

Enterome scientists contribute to extensive new genomic and proteomic catalog to enhance analysis of the gut microbiome and understanding of its role in human health

Enterome scientists contribute to extensive new genomic and proteomic catalog to enhance analysis of the gut microbiome and understanding of its role in human health

Published by international research collaboration in Nature Biotechnology

Paris, France and Cambridge, MA, USA – August 3, 2020

ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, notes a new academic publication describing the creation of the most comprehensive and unified catalog to-date of genomic and proteomic data from the human gut microbiome.

The publication in Nature Biotechnology (Almeida, et al, ref. 1), reports on the establishment of a catalog of more than 200,000 reference genomes from over 4,600 species of human gut bacteria.

The research was conducted by an international collaboration involving major academic institutes, such as the European Bioinformatics Institute (UK), Sanger Institute (UK), University of California, San Francisco (USA), Chan Zuckerberg BioHub (USA), University of Trento (Italy), University of Queensland (Australia), Joint Genome Institute (USA) and Enterome (France).

These reference catalogs build on previous global projects aimed at characterizing the human gut microbiome (such as the Human Microbiome Project). The goal of this research is to enable a better understanding of the functions and interactions of bacterial species in the gut microbiome and link to their roles in human health – linking genotype to phenotype within specific clinical contexts, such as during inflammatory diseases, metabolic diseases and cancer.

Enterome has further expanded on this work to assemble the most comprehensive and annotated dataset of peptides and proteins from the gut microbiome (Enterome’s MetaSecretome dataset). This dataset underpins Enterome’s proprietary OncoMimics and EndoMimics platforms, which are being applied to identify and develop novel orally administered, potent and well-tolerated next-generation therapeutics.

Christophe Bonny, Chief Scientific Officer of Enterome, said: “Enterome has a wealth of expertise and powerful technologies designed to explore and analyze the functional content of the human gut microbiome. We are focused on applying our expertise and tools to address in silico large-scale data analysis of microbiome genes and proteins to develop novel drugs for major diseases. We are thrilled that these capabilities have been recognized by our prestigious collaboration partners, and that we have been able to contribute to these important new genomic and proteomic resources. We are confident that these new resources will contribute to an even better understanding of how to leverage the influence of the gut microbiome to improve human health.”

Reference

1. Almeida, A., Nayfach, S., Boland, M. et al. A unified catalog of 204,938 reference genomes from the human gut microbiome. Nat Biotechnol (2020). https://doi.org/10.1038/s41587-020-0603-3

top-header

About ENTEROME

Enterome is a world leader in the discovery and development of novel pharmaceuticals based on its unrivalled understanding of the interaction between the gut microbiome and the immune system (the ‘microbiome-immunoinflammation axis’). Enterome is leveraging this expertise to develop a pipeline of clinical and pre-clinical candidates (small molecules, proteins and peptides) with a focus on cancer, autoimmune, inflammatory and metabolic diseases.

Enterome has two unique platforms that are generating highly promising drug candidates:

OncoMimics: highly effective, off-the-shelf immunotherapies against cancers (EO2401, EO2463). EO2401 is in Phase 1/2 clinical trials in patients with glioblastoma and expected to enter first clinical trials in patients with adrenal malignancies during mid-2020. EO2463, is being prepared as a clinical candidate for B-cell malignancies.

EndoMimics: a new generation of biologics for inflammatory diseases (EM101), Type 2 diabetes and inflammatory bowel disease.

These highly productive platforms have been created using Enterome’s world-leading Metasecretome technology, which gives it an unrivalled ability to generate precision drugs by using the natural reservoir of thousands of safe and tolerized effector proteins that are produced by the gut bacteria.

Enterome’s most advanced drug candidate is EB8018 (also referred to as sibofimloc/TAK-018), which selectively blocks the virulence factor FimH, is advancing through clinical trials in Crohn’s disease. EB8018 has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.

Enterome is headquartered in Paris (France) with operations in Boston (US) and is backed by leading venture capital investors.

Enterome
Pierre Belichard, CEO
media@enterome.com

Media Relations
Mark Swallow / Sylvie Berrebi / David Dible
Citigate Dewe Rogerson
Tel. +44 207 638 9571 / enterome@citigatedewerogerson.com

Investors Relations
Melody Carey
Rx Communications Group
Tel. +1 917 322 2571 mcarey@rxir.com

top-header

Download the press release (.pdf format)

 

Comments are closed.

Categories

  • PRESS RELEASES
  • PRESS RELEASES 2021
  • PRESS RELEASES 2020
  • PRESS RELEASES 2019
  • PRESS RELEASES 2018
  • PRESS RELEASES 2017
  • PRESS RELEASES 2016
  • PRESS RELEASES 2015
  • PRESS RELEASES 2014
  • EVENTS
  • CAREERS
  • PRESS
ETEROME-Bioscience

ENTEROME

94/96 avenue Ledru-Rollin
75011 PARIS, FRANCE
Tel : +33 (0)1 75 77 27 85
Email : info@enterome.com

INFORMATIONS

RCS Paris N° 508 580 289
Siret : 50858028900025
NAF : 7211Z
N° TVA : FR40 508 580 289

Legal notice • Privacy Policy • Cookie Policy
2021 ENTEROME — All rights reserved.
Lors de votre navigation sur notre site internet, nous sommes susceptibles de déposer des cookies sur votre appareil à des fins d’analyses et de performances. Vous avez la possibilité d’accepter, de refuser ou de paramétrer le dépôt de cookies.

When you navigate on our website, we may deposit cookies on your device for analysis and performance purposes. You are able to accept, refuse or configure the cookies' deposit. [ Read More ]

Cookie settings Reject Accept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Read more about our Privacy Policy.
Necessary
Always Enabled

The cookies defines under this category are absolutely essential for the website to function. Hence they are loaded by default irrespective if user consent.

CookieDescription
cookielawinfo-checkbox-necessaryThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-non-necessaryThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Non Necessary".
PHPSESSIDThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policyThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Analytics

Analytics cookies help us understand how our visitors interact with the website. It helps us understand the number of visitors, where the visitors are coming from, and the pages they navigate. The cookies collect this data and are reported anonymously.

CookieDescription
_gaThis cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, camapign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assigns a randoly generated number to identify unique visitors.
_gidThis cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the wbsite is doing. The data collected including the number visitors, the source where they have come from, and the pages viisted in an anonymous form.

Performance

These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is aggregated and therefore anonymous. It is only used to improve how a website works.

CookieDescription
_gatThis cookies is installed by Google Universal Analytics to throttle the request rate to limit the colllection of data on high traffic sites.